NKGen Biotech Inc (NKGN)

NKGen Biotech Inc is a clinical-stage biotechnology company listed on OTC Markets under the ticker NKGN. The company focuses on developing and commercializing cell therapies for neurodegenerative and oncology-related indications using activated natural killer (NK) cells. Its pipeline includes SNK01, an autologous NK cell therapy candidate being studied in a Phase I/IIa trial for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, as well as SNK02, an allogeneic NK cell therapy that has completed Phase 1 testing. NKGen is also advancing a HER2-CAR NK cell therapy candidate in preclinical development for refractory solid tumors. The company has a strategic partnership with HekaBio K.K. to support clinical development, regulatory work, manufacturing, and commercialization in Japan, and it holds a license agreement with NKMAX Co., Ltd. for research and development of its NK cell program. NKGen Biotech was founded in 2017 and is headquartered in Santa Ana, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.